Tindamax: profile and news
Mission Pharmacal completes phase III Tindamax study May 9, 2006
Mission Pharmacal has successfully completed a randomized multi-center trial evaluating two dosing regimens of Tindamax for the treatment of bacterial vaginosis ... - Pharmaceutical Business Review
(PRN) Mission Pharmacal Acquires Tindamax(R): Treatment for ... Apr 20, 2006
ANTONIO, April 20 /PRNewswire/ -- Mission Pharmacal today announced that it has acquired the US manufacturing and commercial rights for Tindamax(R) (tinidazole ... - Houston Chronicle,
Mission Pharmacal Completes Phase III Study Of Tindamax(R) For The ... May 9, 2006
...the successful completion of a randomized, placebo-controlled, double blind multi-center trial evaluating two dosing regimens of Tindamax(R) (tinidazole) for ... - Medical News Today (press release),
Mission Pharmacal Acquires Tindamax; Treatment for Trichomoniasis ... Apr 20, 2006
Texas, April 20, 2006 -- Mission Pharmacal today announced that it has acquired the US manufacturing and commercial rights for Tindamax* (tinidazole tablets ... - PharmaLive.com (press release),
Most Common Curable STD a Significant Public Health Concern When ... May 9, 2006
SAN ANTONIO, Texas, May 9 /PRNewswire/ -- Mission Pharmacal today announced the launch of a new Web resource, http://www.Tindamax.com , designed to educate ... - Yahoo! News (press release)
Most Common Curable STD a Significant Public Health Concern When ... May 9, 2006
SAN ANTONIO, Texas — Mission Pharmacal today announced the launch of a new Web resource, http://www.tindamax.com/ , designed to educate visitors about ... - Drug Newswire (press release),
Most Common Curable STD a Significant Public Health Concern When ... May 10, 2006
SAN ANTONIO, Texas, May 9, 2006 -- Mission Pharmacal today announced the launch of a new Web resource, www.Tindamax.com, designed to educate visitors about ... - PharmaLive.com (press release),
Most Common Curable STD a Significant Public Health Concern When ... May 9, 2006
...http://www.Tindamax.com , designed to educate visitors about trichomoniasis, or "trich," the most common curable sexually transmitted disease (STD) in the ... - PharmaLive.com (press release),
Mission Pharmacal buys rights to STD prescription drug therapy Apr 21, 2006
Mission Pharmacal has purchased the US manufacturing and commercial rights for the prescription drug Tindamax, the company said Thursday. ... - Bizjournals.com,
Briefs: Mission Pharmacal acquires drug rights Apr 21, 2006
...disease. Tindamax is a prescription drug for trichomoniasis, a common STD contracted by about 7.4 million people each year. The ... - San Antonio Express (subscription),
Deceptive Prescription Drug Marketing Is Widespread And Dangerous May 3, 2006
To illustrate the problem, the report includes six case studies in deceptive marketing of: Vioxx, OxyContin, Paxil, Accutane, Neurontin and Tindamax. ... - MASSPIRG,
Drug makers under fire May 4, 2006
...industry, as evidenced by recent scandals involving Vioxx and OxyContin for pain; Accutane for acne; Neurontin for epilepsy and an antibiotic called Tindamax. ... - Cherry Hill Courier Post,
Deceptive Prescription Drug Marketing Tactics ‘Common and ... May 3, 2006
FDA.�. The report includes six case studies of deceptive marketing: Vioxx, OxyContin, Paxil, Accutane, Neurotin and Tindamax. The ... - Common Dreams (press release),
New licensing and development agreements. Apr 26, 2006
Mission Pharmacal (San Antonio, TX, www.missionpharmacal.com) has acquired the US rights to manufacture and commercialize Tindamax (tinidazole) tablets from ... - PharmExec.com,
